Veru (VERU) Cash & Equivalents (2010 - 2026)
Veru (VERU) posted quarterly Cash & Equivalents of $27.6 million for Q1 2026, up 37.86% year-over-year from $20.0 million in Q1 2025, and down 16.35% quarter-over-quarter from $33.0 million in Q4 2025.
Veru (VERU) Cash & Equivalents (2010 - 2026) Analysis & Trends
Veru (VERU) has reported Cash & Equivalents for 17 consecutive years, with $27.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash & Equivalents rose 37.86% year-over-year to $27.6 million; the TTM figure through Mar 2026 stood at $27.6 million (up 37.86% YoY), while the FY2025 annual figure was $15.8 million, down 36.61% from the prior year.
- Cash & Equivalents slipped to $27.6 million in Q1 2026 per VERU's latest filing, from $33.0 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $112.0 million in Q1 2022 and bottomed at $9.6 million in Q3 2023.
- Historically, Cash & Equivalents has averaged $38.6 million across 5 years, with a median of $27.6 million in 2026.
- Annual changes were most pronounced in 2023 — Cash & Equivalents slumped 88.0% — and 2024, when it jumped 158.86%.
- Veru's Cash & Equivalents stood at $46.9 million in 2022, then declined by 13.53% to $40.6 million in 2023, then slumped by 34.43% to $26.6 million in 2024, then rose by 24.0% to $33.0 million in 2025, then fell by 16.35% to $27.6 million in 2026.
- Business Quant data shows VERU's Cash & Equivalents at $27.6 million in Q1 2026, $33.0 million in Q4 2025, and $15.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 3.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.72 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.71 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 8.93 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 544.80 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 811.99 Mn |
| 10 | Veru | 60.85 Mn | 35.06 Mn | - | 23.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 23.88 Mn |
| Mar 31, 2026 | 27.60 Mn |
| Dec 31, 2025 | 32.99 Mn |
| Sep 30, 2025 | 15.79 Mn |
| Jun 30, 2025 | 15.01 Mn |
| Mar 31, 2025 | 20.02 Mn |
| Dec 31, 2024 | 26.61 Mn |
| Sep 30, 2024 | 24.92 Mn |
| Jun 30, 2024 | 29.15 Mn |
| Mar 31, 2024 | 34.74 Mn |
| Dec 31, 2023 | 40.58 Mn |
| Sep 30, 2023 | 9.63 Mn |
| Jun 30, 2023 | 16.21 Mn |
| Mar 31, 2023 | 23.50 Mn |
| Dec 31, 2022 | 46.93 Mn |
| Sep 30, 2022 | 80.19 Mn |
| Jun 30, 2022 | 100.55 Mn |
| Mar 31, 2022 | 112.02 Mn |
| Dec 31, 2021 | 116.10 Mn |
| Sep 30, 2021 | 122.36 Mn |